ARD:抗纤维化因子KLF4在真皮成纤维细胞中被miR-10/TFAP2A/TBX5轴抑制

2022-01-20 网络 网络

KLF4在系统性硬化症(SSc)的皮肤成纤维细胞中具有抗纤维化作用,其表达受到TmiR-10/TFAP2A/TBX5轴的抑制。

       背景:系统性硬化症(SSc)是一种病因不明的复杂疾病,其中炎症和纤维化导致多器官损伤。目前还没有有效的治疗方法可以阻止或逆转纤维化的进展,因此迫切需要对疾病发病机制提供新见解并确定新的潜在治疗靶点的研究。SSc双胞胎的疾病一致性较低,暗示表观遗传学在疾病中的作用。

       方法:研究者使用来自与SSc不一致的独特双胞胎队列(15对)的皮肤成纤维细胞(dFB)的全局基因表达(RNA-seq)和全基因组DNA甲基化分析来识别这种疾病的病理学分子特征。研究者使用体外、离体和体内模型验证了这些发现。

结果:该研究揭示了不同的差异表达和甲基化基因,包括参与干细胞分化和发育程序的几种转录因子(KLF4TBX5TFAP2AHOXB3HOXB8同源框基因)。HOX基因抑制microRNA10a/10b的表达。miR10a位于17号染色体上HOXB4 的上游,而miR10b位于2号染色体上HOXD4的上游。对SSc患者皮肤成纤维细胞的两种microRNA 的分析显示这些microRNA水平降低。因此,microRNA10a/10b的靶向基因TFAP2ATBX5 在这双胞胎队列中确实上调了。正常真皮成纤维细胞中miR10a miR10b的沉默导致 TFAP2ATBX5mRNA上调SSc成纤维细胞中恢复正常水平的miR10a 10b 可使 TFAP2ATBX5的表达正常化,并降低I型胶原蛋白的异常表达。研究者继续检查胚胎干细胞转录因子,发现SRY-box 2 (SOX2) 表达增强和KLF4 表达降低,特别是在SSc的早期阶段。KLF4表达受到TBX5TFAP2A的抑制。结果还表明KLF4具有抗纤维化作用,其在成纤维细胞中的条件性敲除促进了纤维化表型

       结论:该研究的数据支持表观遗传失调在介导dFBsSSc易感性中的作用,说明 CpG甲基化、miRNA和转录因子在SSc发病机制中的复杂相互作用,并强调未来使用表观遗传修饰剂作为治疗的潜力。

 

出处:

Malaab M, Renaud L, Takamura N, et al. Antifibrotic factor KLF4 is repressed by the miR-10/TFAP2A/TBX5 axis in dermal fibroblasts: insights from twins discordant for systemic sclerosis. Annals of the Rheumatic Diseases 2022;81:268-277.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1968682, encodeId=38a5196868299, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun May 29 12:25:15 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930856, encodeId=f1d81930856f7, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon May 02 20:25:15 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053962, encodeId=1481205396215, content=<a href='/topic/show?id=d7545560388' target=_blank style='color:#2F92EE;'>#抗纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55603, encryptionId=d7545560388, topicName=抗纤维化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Dec 04 02:25:15 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307179, encodeId=42dc130e17901, content=<a href='/topic/show?id=6dab540565f' target=_blank style='color:#2F92EE;'>#成纤维细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54056, encryptionId=6dab540565f, topicName=成纤维细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462865, encodeId=f9801462865f0, content=<a href='/topic/show?id=fbbce726228' target=_blank style='color:#2F92EE;'>#纤维细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77262, encryptionId=fbbce726228, topicName=纤维细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c516518840, createdName=marongnuan, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542792, encodeId=c6a81542e9261, content=<a href='/topic/show?id=b37e1052940' target=_blank style='color:#2F92EE;'>#KLF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10529, encryptionId=b37e1052940, topicName=KLF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20e513483998, createdName=124986d2m13暂无昵称, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186495, encodeId=583711864950f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1646442901, createdName=ms4000001513304915, createdTime=Thu Jan 20 17:07:51 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
    2022-05-29 mgqwxj
  2. [GetPortalCommentsPageByObjectIdResponse(id=1968682, encodeId=38a5196868299, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun May 29 12:25:15 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930856, encodeId=f1d81930856f7, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon May 02 20:25:15 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053962, encodeId=1481205396215, content=<a href='/topic/show?id=d7545560388' target=_blank style='color:#2F92EE;'>#抗纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55603, encryptionId=d7545560388, topicName=抗纤维化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Dec 04 02:25:15 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307179, encodeId=42dc130e17901, content=<a href='/topic/show?id=6dab540565f' target=_blank style='color:#2F92EE;'>#成纤维细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54056, encryptionId=6dab540565f, topicName=成纤维细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462865, encodeId=f9801462865f0, content=<a href='/topic/show?id=fbbce726228' target=_blank style='color:#2F92EE;'>#纤维细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77262, encryptionId=fbbce726228, topicName=纤维细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c516518840, createdName=marongnuan, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542792, encodeId=c6a81542e9261, content=<a href='/topic/show?id=b37e1052940' target=_blank style='color:#2F92EE;'>#KLF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10529, encryptionId=b37e1052940, topicName=KLF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20e513483998, createdName=124986d2m13暂无昵称, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186495, encodeId=583711864950f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1646442901, createdName=ms4000001513304915, createdTime=Thu Jan 20 17:07:51 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
    2022-05-02 smallant2002
  3. [GetPortalCommentsPageByObjectIdResponse(id=1968682, encodeId=38a5196868299, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun May 29 12:25:15 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930856, encodeId=f1d81930856f7, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon May 02 20:25:15 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053962, encodeId=1481205396215, content=<a href='/topic/show?id=d7545560388' target=_blank style='color:#2F92EE;'>#抗纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55603, encryptionId=d7545560388, topicName=抗纤维化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Dec 04 02:25:15 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307179, encodeId=42dc130e17901, content=<a href='/topic/show?id=6dab540565f' target=_blank style='color:#2F92EE;'>#成纤维细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54056, encryptionId=6dab540565f, topicName=成纤维细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462865, encodeId=f9801462865f0, content=<a href='/topic/show?id=fbbce726228' target=_blank style='color:#2F92EE;'>#纤维细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77262, encryptionId=fbbce726228, topicName=纤维细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c516518840, createdName=marongnuan, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542792, encodeId=c6a81542e9261, content=<a href='/topic/show?id=b37e1052940' target=_blank style='color:#2F92EE;'>#KLF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10529, encryptionId=b37e1052940, topicName=KLF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20e513483998, createdName=124986d2m13暂无昵称, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186495, encodeId=583711864950f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1646442901, createdName=ms4000001513304915, createdTime=Thu Jan 20 17:07:51 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1968682, encodeId=38a5196868299, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun May 29 12:25:15 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930856, encodeId=f1d81930856f7, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon May 02 20:25:15 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053962, encodeId=1481205396215, content=<a href='/topic/show?id=d7545560388' target=_blank style='color:#2F92EE;'>#抗纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55603, encryptionId=d7545560388, topicName=抗纤维化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Dec 04 02:25:15 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307179, encodeId=42dc130e17901, content=<a href='/topic/show?id=6dab540565f' target=_blank style='color:#2F92EE;'>#成纤维细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54056, encryptionId=6dab540565f, topicName=成纤维细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462865, encodeId=f9801462865f0, content=<a href='/topic/show?id=fbbce726228' target=_blank style='color:#2F92EE;'>#纤维细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77262, encryptionId=fbbce726228, topicName=纤维细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c516518840, createdName=marongnuan, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542792, encodeId=c6a81542e9261, content=<a href='/topic/show?id=b37e1052940' target=_blank style='color:#2F92EE;'>#KLF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10529, encryptionId=b37e1052940, topicName=KLF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20e513483998, createdName=124986d2m13暂无昵称, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186495, encodeId=583711864950f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1646442901, createdName=ms4000001513304915, createdTime=Thu Jan 20 17:07:51 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1968682, encodeId=38a5196868299, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun May 29 12:25:15 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930856, encodeId=f1d81930856f7, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon May 02 20:25:15 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053962, encodeId=1481205396215, content=<a href='/topic/show?id=d7545560388' target=_blank style='color:#2F92EE;'>#抗纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55603, encryptionId=d7545560388, topicName=抗纤维化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Dec 04 02:25:15 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307179, encodeId=42dc130e17901, content=<a href='/topic/show?id=6dab540565f' target=_blank style='color:#2F92EE;'>#成纤维细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54056, encryptionId=6dab540565f, topicName=成纤维细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462865, encodeId=f9801462865f0, content=<a href='/topic/show?id=fbbce726228' target=_blank style='color:#2F92EE;'>#纤维细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77262, encryptionId=fbbce726228, topicName=纤维细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c516518840, createdName=marongnuan, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542792, encodeId=c6a81542e9261, content=<a href='/topic/show?id=b37e1052940' target=_blank style='color:#2F92EE;'>#KLF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10529, encryptionId=b37e1052940, topicName=KLF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20e513483998, createdName=124986d2m13暂无昵称, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186495, encodeId=583711864950f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1646442901, createdName=ms4000001513304915, createdTime=Thu Jan 20 17:07:51 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1968682, encodeId=38a5196868299, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun May 29 12:25:15 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930856, encodeId=f1d81930856f7, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon May 02 20:25:15 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053962, encodeId=1481205396215, content=<a href='/topic/show?id=d7545560388' target=_blank style='color:#2F92EE;'>#抗纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55603, encryptionId=d7545560388, topicName=抗纤维化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Dec 04 02:25:15 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307179, encodeId=42dc130e17901, content=<a href='/topic/show?id=6dab540565f' target=_blank style='color:#2F92EE;'>#成纤维细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54056, encryptionId=6dab540565f, topicName=成纤维细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462865, encodeId=f9801462865f0, content=<a href='/topic/show?id=fbbce726228' target=_blank style='color:#2F92EE;'>#纤维细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77262, encryptionId=fbbce726228, topicName=纤维细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c516518840, createdName=marongnuan, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542792, encodeId=c6a81542e9261, content=<a href='/topic/show?id=b37e1052940' target=_blank style='color:#2F92EE;'>#KLF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10529, encryptionId=b37e1052940, topicName=KLF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20e513483998, createdName=124986d2m13暂无昵称, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186495, encodeId=583711864950f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1646442901, createdName=ms4000001513304915, createdTime=Thu Jan 20 17:07:51 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1968682, encodeId=38a5196868299, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun May 29 12:25:15 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930856, encodeId=f1d81930856f7, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon May 02 20:25:15 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053962, encodeId=1481205396215, content=<a href='/topic/show?id=d7545560388' target=_blank style='color:#2F92EE;'>#抗纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55603, encryptionId=d7545560388, topicName=抗纤维化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Dec 04 02:25:15 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307179, encodeId=42dc130e17901, content=<a href='/topic/show?id=6dab540565f' target=_blank style='color:#2F92EE;'>#成纤维细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54056, encryptionId=6dab540565f, topicName=成纤维细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462865, encodeId=f9801462865f0, content=<a href='/topic/show?id=fbbce726228' target=_blank style='color:#2F92EE;'>#纤维细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77262, encryptionId=fbbce726228, topicName=纤维细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c516518840, createdName=marongnuan, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542792, encodeId=c6a81542e9261, content=<a href='/topic/show?id=b37e1052940' target=_blank style='color:#2F92EE;'>#KLF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10529, encryptionId=b37e1052940, topicName=KLF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20e513483998, createdName=124986d2m13暂无昵称, createdTime=Sat Jan 22 03:25:15 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186495, encodeId=583711864950f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1646442901, createdName=ms4000001513304915, createdTime=Thu Jan 20 17:07:51 CST 2022, time=2022-01-20, status=1, ipAttribution=)]
    2022-01-20 ms4000001513304915

    学习#学习#

    0

相关资讯

Autoimmun Rev:静脉注射免疫球蛋白可有效改善系统性硬化症的皮肤受累情况

静脉注射免疫球蛋白(IVIG)是系统性硬化症SSc的一种新治疗方法。据推测,IVIG具有免疫调节和抗纤维化的活性。IVIG通常具有良好的耐受性,副作用很少。

Arthritis Rheumatol:系统性硬化症患者的舒张功能障碍的危险因素和对死亡率的影响

DD与SSc患者死亡风险增加独立相关。医务人员应在SSc患者中解决潜在的可改变危险因素,包括CAD和肥胖症,以降低患者死亡风险。

A&R: B细胞耗竭通过抑制系统性硬化症小鼠模型中的促纤维化巨噬细胞分化来抑制纤维化

这项研究是为了探索B细胞耗竭对系统性硬化症 (SSc) 纤维化的影响及其作用机制。

Lancet Rheumatology: 雷诺现象患者向系统性硬化症的进展

不存在ANA是一种强有力的保护因素,可识别出患系统性硬化症的风险非常低的患者,而雷诺现象患者中存在一两个VEDOSS标准则表明,随着时间的推移,患系统性硬化症的风险会逐渐升高。

Lancet Rheumatology: 硬皮病患者为中心的干预网络 (SPIN) 队列中的疼痛水平和相关因素:一项多中心横断面研究

疼痛在系统性硬化症患者中很常见。控制社会人口学变量后,更大的疼痛与多种系统性硬化症相关的症状有关,包括关节挛缩、手指溃疡、胃肠道受累、皮肤受累和重叠综合征的存在。

结缔组织疾病中的肺动脉高压:新证据?新挑战?

肺动脉高压是系统性硬化症、混合性结缔组织病和系统性红斑狼疮等不同结缔组织疾病的致命并发症。